Axon Enterprise (NASDAQ:AXON) Posts Earnings Results, Beats Estimates By $0.58 EPS

Key Points

• Axon Enterprise reported earnings of $0.85 per share, significantly missing analysts' estimates of $1.54 by $0.69.
• Despite the earnings miss, Axon stock rose 0.3% to $744.88 following the earnings release, with a market capitalization of $57.99 billion.
• Multiple equity analysts have expressed positive forecasts, raising target prices for Axon stock, reflecting a consensus average price target of $772.08 with a rating of "Moderate Buy."

Axon Enterprise (NASDAQ:AXON - Get Free Report) posted its quarterly earnings results on Monday. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.58, Briefing.com reports. The firm had revenue of $668.54 million during the quarter, compared to analysts' expectations of $641.77 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The firm's revenue for the quarter was up 32.6% on a year-over-year basis. During the same period in the prior year, the company posted $1.20 earnings per share. Axon Enterprise updated its FY 2025 guidance to EPS.

Axon Enterprise Price Performance

Shares of AXON stock traded down $15.58 during trading hours on Friday, hitting $855.39. The company's stock had a trading volume of 178,455 shares, compared to its average volume of 706,397. The business has a fifty day moving average of $772.30 and a 200-day moving average of $663.05. The stock has a market cap of $67.15 billion, a price-to-earnings ratio of 211.21, a P/E/G ratio of 19.36 and a beta of 1.36. Axon Enterprise has a twelve month low of $346.71 and a twelve month high of $885.91. The company has a current ratio of 2.95, a quick ratio of 2.62 and a debt-to-equity ratio of 0.63.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Raymond James Financial reissued an "outperform" rating and set a $855.00 price target (up from $645.00) on shares of Axon Enterprise in a report on Tuesday. Needham & Company LLC set a $870.00 price target on shares of Axon Enterprise and gave the stock a "buy" rating in a report on Tuesday. JPMorgan Chase & Co. increased their price target on shares of Axon Enterprise from $730.00 to $850.00 and gave the stock an "overweight" rating in a report on Thursday, July 17th. Craig Hallum raised shares of Axon Enterprise from a "hold" rating to a "buy" rating and set a $900.00 price target for the company in a report on Tuesday. Finally, Bank of America increased their price target on shares of Axon Enterprise from $895.00 to $1,000.00 and gave the stock a "buy" rating in a report on Wednesday. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $837.69.

Insiders Place Their Bets

In other news, Director Michael Garnreiter sold 5,913 shares of the stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $760.00, for a total value of $4,493,880.00. Following the sale, the director directly owned 17,740 shares in the company, valued at $13,482,400. This represents a 25.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Caitlin Elizabeth Kalinowski sold 1,300 shares of the firm's stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $738.84, for a total transaction of $960,492.00. Following the sale, the director owned 4,829 shares in the company, valued at approximately $3,567,858.36. This trade represents a 21.21% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 34,642 shares of company stock valued at $25,090,528. Corporate insiders own 4.40% of the company's stock.

Hedge Funds Weigh In On Axon Enterprise

A number of large investors have recently bought and sold shares of AXON. Brighton Jones LLC purchased a new position in Axon Enterprise during the fourth quarter worth approximately $480,000. Empowered Funds LLC raised its stake in shares of Axon Enterprise by 8.4% in the 1st quarter. Empowered Funds LLC now owns 2,028 shares of the biotechnology company's stock valued at $1,067,000 after acquiring an additional 157 shares during the period. NewEdge Advisors LLC raised its stake in shares of Axon Enterprise by 41.1% in the 1st quarter. NewEdge Advisors LLC now owns 2,294 shares of the biotechnology company's stock valued at $1,207,000 after acquiring an additional 668 shares during the period. Finally, Woodline Partners LP raised its stake in shares of Axon Enterprise by 40.6% in the 1st quarter. Woodline Partners LP now owns 6,932 shares of the biotechnology company's stock valued at $3,646,000 after acquiring an additional 2,003 shares during the period. Hedge funds and other institutional investors own 79.08% of the company's stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.